Biotech RadarJobs updated

COMPANY

City Therapeutics

HQ: Cambridge, MA source · citytx.com ↗

Clinical Phase 1

8 open jobs · last seen Oct 23, 2026 · 6 sources

City Therapeutics™ is a clinical-stage biotechnology company developing the generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. From company website Source · Oct 12, 2026

Keywords: Factor V Leiden Prothrombin G20210A Venous Thromboembolism Stargardt Disease 1 STGD1 CITY-RBP4

Location: Cambridge, MA · source · Oct 12, 2026

Profile checked Oct 10, 2026

Since the raise (Jun 8, 2026): 8 of 8 open jobs were first seen after it.

8Open jobs$99.5MRaised (2 yrs)2Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Director, Corporate DevelopmentCambridge, Massachusetts, United StatesOct 21, 2026Oct 22, 2026
VP, Quality AssuranceCambridge, MAOct 19, 2026Oct 20, 2026
Vice President, Drug Safety and PharmacovigilanceCambridge, MAOct 16, 2026Oct 17, 2026
Senior Director, Clinical Development (Medical Director)Cambridge, Massachusetts, United StatesSep 30, 2026Oct 9, 2026
Senior Director, Assistant Corporate ControllerCambridge, Massachusetts, United StatesSep 28, 2026Oct 9, 2026

See all 8 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (8 open jobs at last check). source ↗
  2. Trial start 1: A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants source ↗
  3. Raise Private equity round — Series B: $99.5M (total, as published), announced Jun 8, 2026. Source: company's own press page. source ↗
  4. Trial start Phase 1: A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, a source ↗
  5. Partnership Partnership / licensing announced May 27, 2025. Source: company's own press page. source ↗
  6. Partnership Partnership / licensing announced Jan 10, 2025. Source: company's own press page. source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 8

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Director, Corporate DevelopmentCambridge, Massachusetts, United StatesOct 21, 2026Oct 22, 2026Not stated
VP, Quality AssuranceCambridge, MAOct 19, 2026Oct 20, 2026Not stated
Vice President, Drug Safety and PharmacovigilanceCambridge, MAOct 16, 2026Oct 17, 2026Not stated
Senior Director, Clinical Development (Medical Director)Cambridge, Massachusetts, United StatesSep 30, 2026Oct 9, 2026Senior
Senior Director, Assistant Corporate ControllerCambridge, Massachusetts, United StatesSep 28, 2026Oct 9, 2026Senior
Associate Director, Clinical PharmacologyCambridge, Massachusetts, United StatesJun 3, 2026Oct 9, 2026Senior
Associate Director, Toxicology (Nonclinical Safety Evaluation)Cambridge, Massachusetts, United StatesMay 27, 2026Oct 9, 2026Senior
Join the RNAi revolution!Cambridge, MassachusettsOct 16, 2024Oct 9, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $99.5M. Last 2 years.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT07430397A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous ThromboembolismPhase 1RecruitingJan 22, 20262028-03 (estimated)
NCT07836452A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants1Recruiting2026-092028-02 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback